NASDAQ

BridgeBio Pharma, Inc.

BBIO

2 stories

$13B Market cap · 2026-10-23

BridgeBio Pharma reported Q2 revenue of $243.7 million and has three Priority Review NDAs, while $1 billion in convertible preferred…

Terry Chrisomalis Oct 13 2 clicks

BridgeBio Pharma raised Attruby peak-sales guidance as kidney-benefit data, fewer hospital days and competitor setbacks strengthen its…

Atticus Analysis Sep 10 1 click